Related Experiment Videos
Targeting split vaccines to the endosome improves vaccination.
Hermann Wagner1, Antje Heit, Frank Schmitz
1Institute of Medical Microbiology, Immunology and Hygiene, Trogerstrasse. 9, 81675 Munich, Germany. h.wagner@lrz.tu-muenchen.de
Current Opinion in Biotechnology
|November 25, 2004
Summary
Recombinant vaccines show poor immunogenicity because antigens don't access the MHC class I pathway. Targeting Toll-like receptor 9 ligands with antigens to dendritic cells enhances immunogenicity, improving vaccine effectiveness.
Area of Science:
- Immunology
- Vaccinology
- Molecular Biology
Background:
- Split vaccines using recombinant antigens (Ag) have lower immunogenicity than live vaccines.
- Poor immunogenicity is linked to exogenous Ag failing to access the major histocompatibility complex (MHC) class I processing pathway for cross-presentation.
Purpose of the Study:
- To explore strategies for enhancing the immunogenicity of recombinant vaccines.
- To investigate the role of Toll-like receptor 9 (TLR9) ligands in improving antigen cross-presentation.
Main Methods:
- Targeting proteinaceous Ag and TLR9 ligands to the endosomes of dendritic cells.
- Evaluating the resulting antigen-specific immune responses.
Main Results:
- Co-delivery of Ag and TLR9 ligands to dendritic cells significantly enhanced antigen immunogenicity.
- The induced immunogenicity was comparable to that of live vaccines.
Conclusions:
- Enforced endocytosis of Ag combined with the adjuvant effect of TLR9 ligands is crucial for efficient cross-presentation of exogenous Ag.
- This strategy effectively promotes cross-priming of MHC class I-restricted CD8 T effector cells, improving vaccine efficacy.